Navigation Links
Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President
Date:7/30/2014

WESTFORD, Mass., July 30, 2014 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that the Board of Directors has promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to President of the Company, effective August 1, 2014.  Baker, 53, will continue to serve as CFO and will take the title of President from Michael Davin, who remains Chairman and Chief Executive Officer.

"Tim has been a valued member of Cynosure's leadership team since joining the Company as Executive Vice President and CFO in 2004," Davin said. "He is focused on continuously improving our financial and operating performance and committed to delivering value for our shareholders. Tim played a key strategic role in our June 2013 acquisition of Palomar Medical Technologies; his operational skills and business expertise were keys to successfully completing the integration in just 12 months. We congratulate Tim on this well-deserved promotion."

Before joining Cynosure, Baker served as Vice President, Finance at Stryker Biotech, a division of medical products and services provider Stryker Corporation. From July 2000 to June 2003, Baker served as President and Chief Financial Officer at Photoelectron Corp., a provider of miniature X-ray systems for radiation therapy. From January 1996 to July 2000, he served as Chief Financial Officer and Vice President of Operations at Radionics, Inc., a provider of surgical devices. Baker is a certified public accountant and holds an MBA in operations management.

About Cynosure, Inc.

Cynosure develops and markets laser and light-based aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands.  Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light.  Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.  For corporate or product information, visit Cynosure's website at www.cynosure.com.

Contact
Scott Solomon
Vice President
Sharon Merrill Associates
617-542-5300
cyno@investorrelations.com

Photo - http://photos.prnewswire.com/prnh/20140729/130910


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cynosure Reports Second-Quarter 2014 Financial Results
2. Cynosure to Present at 16th Annual Needham Growth Conference
3. Cynosure Announces Successful Settlement of Patent Infringement Lawsuits Against Tria Beauty
4. Cynosure Announces Sale of Burlington, MA Office Building
5. Cynosure Reports Third-Quarter 2013 Financial Results
6. Cynosure Completes Acquisition of Palomar Medical Technologies
7. Cynosure Added to the S&P SmallCap 600 Index
8. Cynosure to Present at UBS Global Healthcare Conference
9. Cynosure Reports First-Quarter 2013 Financial Results
10. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
11. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Allergy Diagnostics ... products and tests that are used to determine ... peanuts, milk, or drugs etc. in the samples ... the immune system. The report on global allergy ... of the market. The report consists of an ...
(Date:12/8/2016)... Connecticut , 8 de dezembro de 2016  A Mederi Therapeutics ... terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pennsylvania Cable Network (PCN) during the summer of 2016. The program was made ... by the United States Department of Health and Human Services Administration. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
Breaking Medicine News(10 mins):